GRObio’s groundbreaking science
We have developed the only synthetic biology platform that grants access to the full universe of non-standard amino acids (NSAAs) with novel therapeutic applications.
More About Us
The GRO Platform
The GRO platform removes the barriers historically associated with protein therapeutics.
By granting access to the full universe of non-standard amino acids (NSAAs), the GRO platform overcomes the limitations on potency, immunogenicity, and stability impairing therapeutics constructed from the 20 standard amino acids.
LEARN MORE
ProGly™ Programs
Our programs are focused in two primary areas: reversing autoimmunity and eliminating immunogenicity.
ProGly™ NSAAs are pre-glycosylated amino acids installed by the GRO platform that provide precise control over the glycan composition on any protein. We use this approach to reeducate the immune system to reverse autoimmune processes.
LEARN MORE
Featured News
Biotech TV Podcast: George Church on founder-led companies, synthetic biology, the future of biotechnology, and more
GRObio CEO, Dan Mandell, interviews professor George Church about the Genomically Recoded Organisms (GRO) platform that Dan spun out of his lab, asks him what technologies he is working on…
Read More
Endpoints News: George Church Spinout Raises $60M for Protein Therapies from Genomically Recoded Organisms
Ryan Cross interviewed our CEO, Dan Mandell, PhD, about how the Company’s GRO platform expands the limited amino acid alphabet that nature uses to make proteins, and how our Series…
Read More
Biotech TV: GRO Biosciences Announced a $60 Million Series B Today to Help Advance its Pipeline that is Rooted in Adding Non-Standard Amino Acid (NSAA) Chemistries to Therapies
Biotech TV host Brad Loncar visited GRObio’s office in Cambridge and had a discussion with GRObio CEO Dan Mandell, PhD about the Company’s recent Series B financing. In the interview,…
Read More
